Equillium
phase study of in adults with moderate to severe potential target product profile alternative to with at least comparable efficacy patient administered weekly weekly subcutaneous injection similar to | Equillium
Company
Deck date
February 2024
Slide
26 of 40
Similar slides by Equillium
Investor Presentation
December 2023
Investor Presentation
November 2023
Investor Presentation
August 2023
Related slides by other companies
IPO
August 2021
Investor Presentation
February 2024
Investor Presentation
October 2022
Investor Presentation
February 2023
Other recent decks by Equillium
Investor Presentation
December 2023
Investor Presentation
November 2023
Investor Presentation
August 2023
Results
September 2022
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io